Laurie Lenox

Johnson & Johnson (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index522citations36works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related gene regulation(11), CAR-T cell therapy research(3), Epigenetics and DNA Methylation(2), Hemoglobinopathies and Related Disorders(2), Monoclonal and Polyclonal Antibodies Research(2)

Publications36 total

Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2025Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2025Open Access
Abstract 2445: Extending ENPP3 expression inference from tissue microarrays to whole tissue sections: building a case for automated patient enrichment and IHC scoring
Cancer Research·2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
iScience·2025· 4 citedOpen Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2024Open Access
Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2024Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2024Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2024Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2024Open Access
Abstract LB122: JNJ-87890387, a novel ENPP3 bispecific T-cell redirector (ENPP3xCD3) with tumor selectivity through targeting apical surface antigens
Cancer Research·2024· 1 cited
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Leukemia Research·2023· 18 cited
Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Josh Lauring(26), Regina J. Brown(22), Anna Kalota(22), Jaydeep Mehta(22), Pankaj Mistry(22), Manish R. Patel(22), Meir Preis(21), Friederike Pastore(21), María Vieito(20), Víctor Moreno(20), Anna Spreafico(20), Irene Braña(20), Junchen Gu(20), Judy S. Wang(19), Sofia Genta(19), Aaron R. Hansen(19), Vladimir Galvao(19), Bharvin Patel(19), Bernard Doger(17), Tatiana Hernández(11)